Washington
Q3 2026Lobbying Q3 None last Q2 2025
YoY n/a vs Q3 2025
Members 1 90 days
Buys / sells 0 / 2 2 trades
8 quarters Open in Washington ›
OGN
Organon & Co.$13.75 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $13.75
Market cap
$3.6B
Mid cap
Median target
🔒 Subscribers only
Next earnings
Nov 9
in 14 days
1 year
+94.8%
from $7.06 · Oct 27
30 days
+0.1%
from $13.73
52-week range
$5.70–13.81
−0% from high · low Mar 30
Avg volume 20D
2.22M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$200.3K
1 buyer · 2 sellers · since Mar 31
New fund stakes
6
Q2 2026 13F · 2 exits
Filing reports
15
analyzed by SecBot
Congress trades
2
disclosed
SecBot read BEARISH 2 reports · 90 days
Balance 2 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 9, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- R Apr 27 Organon & Co. filed additional proxy materials in support of its pen…
- R Apr 27 Organon & Co. has entered into a definitive merger agreement with Su…
- A Apr 29 BNP Paribas downgrades
- B May 6 1 insider buy $353.1K at $13.35
- S May 6 1 insider sell $353.1K at $13.35
- R Jun 1 Organon & Co. has filed a preliminary proxy statement (PREM14A) in c…
- I Jun 30 6 funds open new positions (13F)
- S Aug 5 1 insider sell $200.3K at $13.57
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $353.1K at an average $13.35. 2 insiders sold $553.4K.
- InstitutionsBEARISH
Q2 2026: 27 added (6 new), 44 trimmed or exited. Largest new: Pentwater Capital Management $245.1M, Man Group $56.6M.
- TrendUPTREND
0% above its 50-day average.
Who's buying
13F· Q2 20266
new positions
2
exits
$405.3M
in new stakes
| Fund | Move | Value |
|---|---|---|
| Pentwater Capital Management LP | NEW | $245.1M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | TRIM | $204.9M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $70.4M |
| UBS Group AG | ADD | $65.8M |
| Man Group plc | NEW | $56.6M |
| MILLENNIUM MANAGEMENT LLC | TRIM | $46.6M |
| Capula Management Ltd | NEW | $41.3M |
| Magnetar Financial LLC | NEW | $38.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Apr 2026Recent actions
| Date | Firm | Rating |
|---|---|---|
| Apr 29, 2026 | BNP Paribas DOWNGRADE | Neutral |
| Apr 28, 2026 | Piper Sandler UPGRADE | Neutral |
| Feb 24, 2026 | Barclays MAINTAIN | Underweight |
| Dec 9, 2025 | Barclays INITIATE | Underweight |
| Nov 11, 2025 | JP Morgan MAINTAIN | Underweight |
| Nov 11, 2025 | Morgan Stanley MAINTAIN | Equal-Weight |
Insider ledger
Form 4$353.1K
bought · 1 insider
$553.4K
sold · 2 insiders
+3.0%
vs their $13.35 cost
| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 11, 2026 | Arjona Ferreira Juan Camilo Head of R&D & CMO | EXERCISE | 11,519 sh |
| Aug 11, 2026 | Arjona Ferreira Juan Camilo Head of R&D & CMO | TAX W/H | $56.3K |
| Aug 5, 2026 | Drinane Juliana Papa Head of Mfg & Supply | SELL | $200.3K |
| Jun 12, 2026 | ESSNER ROBERT Director | AWARD | $240.0K |
| Jun 12, 2026 | Ezekowitz Alan Director | AWARD | $240.0K |
| Jun 12, 2026 | Gayle Helene D Director | AWARD | $240.0K |
| Jun 12, 2026 | LAZARUS ROCHELLE B Director | AWARD | $240.0K |
| Jun 12, 2026 | Patton Cynthia M Director | AWARD | $240.0K |
Earnings setup
EstimatesNov 9
reports in 14 days
Revision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Congressional trades
OGN trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 2 sells
| Date | Member | Type | Amount |
|---|---|---|---|
| Aug 5, 2026 | Kevin Hern R· HOUSE· Joint account· Organon & Co | SELL | $1,001 - $15,000 |
| Aug 5, 2026 | Kevin Hern R· HOUSE· Joint account· Organon & Co | SELL | $1,001 - $15,000 |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 28, 2026 Event
Aug 18, 2026 SEC Renflexis
WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full presc
A bearish institutional cluster emerged in Organon & Co. (OGN) during 2026-Q2, with 19 funds reducing positions…
INST-CLUSTER — Impact 6/10
Aug 11, 2026 Insider
Arjona Ferreira Juan Camilo acquired via exercise 11,519 shares
Head of R&D & CMO
Aug 11, 2026 Insider
Arjona Ferreira Juan Camilo surrendered for taxes 4,134 shares
Head of R&D & CMO @ $13.62 ($56.3K)
Aug 11, 2026 Earnings calendar
OGN Q2 2026 Earnings Scheduled — 2026-08-11
Aug 5, 2026 Insider
Drinane Juliana Papa sold 14,761 shares
Head of Mfg & Supply @ $13.57 ($200.3K)
Aug 5, 2026 Congress
Kevin Hern sell
$1,001 - $15,000 — House
Aug 5, 2026 Congress
Kevin Hern sell
$1,001 - $15,000 — House
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Aug 28, 2026
FDA
Renflexis
WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Inc
Aug 11, 2026
Earnings date
OGN Q2 2026 Earnings Scheduled — 2026-08-11
Aug 3, 2026
Earnings date
OGN Q2 2026 Earnings Scheduled — 2026-08-03
Jul 2, 2026
FDA
Miudella
WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complic
Jul 2, 2026
FDA
Miudella
WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complic
SecBot reports
15 filings · 6 bullish · 3 bearish · 6 neutral- BEARISH INST-CLUSTERAug 18, 2026
A bearish institutional cluster emerged in Organon & Co. (OGN) during 2026-Q2, with 19 funds…
The heavy selling by quant funds (Citadel, D.E. Shaw, Millennium) and active value manager Kahn Brothers signals growing institutional skepticism about OGN's near-term prospects. Monitor Q3 earnings…
- BEARISH 8-KJul 31, 2026
Organon furnished supplemental non-GAAP financial metrics for Q2 2026 via an 8-K, as it has…
The declining non-GAAP metrics confirm the business is under pressure while the Sun Pharma merger process continues. Traders should monitor for any updates on the merger timeline, regulatory…
- NEUTRAL 8-KJul 17, 2026
Organon filed an 8-K supplementing its definitive proxy statement for the pending Sun Pharma…
The supplemental disclosure is a routine response to deal litigation and does not alter the merger consideration or likely timeline. The July 23 special meeting vote is the next key catalyst…
- BULLISH DEFM14AJun 17, 2026
Organon & Co. shareholders are being asked to vote on the proposed acquisition by Sun…
The deal offers a substantial premium and has committed financing, making it highly likely to close. Shareholders should vote FOR the merger. The stock currently trades near the offer price…
All OGN filing & press-release reports (15)
- INST-CLUSTER reportAug 18, 2026
- 8-K reportJul 31, 2026
- 8-K reportJul 17, 2026
- DEFM14A reportJun 17, 2026
- DEFA14A reportJun 11, 2026
- PREM14A reportJun 1, 2026
- COURT-RULING reportMar 6, 2026
- DEFA14A reportApr 30, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportApr 27, 2026
- DEFA14A reportApr 27, 2026
- DEFA14A reportApr 27, 2026
- DEFA14A reportApr 27, 2026
- 8-K reportApr 27, 2026
- DEFA14A reportApr 24, 2026